From monoclonal antibodies to bispecific antibodies, from multinational giants to innovative biotech companies, a competition centered on extended duration, patient compliance, and therapeutic innovation is now in full swing within the hundred-billion-dollar blue ocean of the ophthalmology market. Later entrants, represented by companies such as Innovent Biologics, RemeGen, NovaBridge Biosciences, and YZY MED, are stepping onto center stage with an unprecedented proactive stance.

Among the transaction's projects, the product involved in the collaboration and licensing between CSPC Megalith Biopharmaceutical and AstraZeneca primarily relates to an innovative peptide molecule along with related technologies and products, currently in the preclinical research stage. It aims to provide a longer-lasting treatment solution for individuals with obesity and weight-related concerns. Furthermore, there exists the possibility for CSPC Megalith Biopharmaceutical and AstraZeneca to engage in strategic collaboration on other related projects in the fields of innovative peptide molecule discovery and long-acting delivery product development.

In mid-2025, EY-Parthenon predicted that the global medical device market would grow at an annual rate of approximately 6%, indicating steady overall market expansion. The medical device industry is undergoing a shift in growth drivers, with multinational corporations (MNCs) intensively divesting or selling off underperforming or slower-growth businesses to focus on higher-growth segments. While certain areas of the industry are losing momentum, which emerging segments are rising to become the new engines of growth?

Leveraging vast volumes of professional literature from both Chinese and international sources, physicians can utilize the DeepSearch feature not only to access the latest frontier guidelines across various specialty fields promptly but also to employ AI tools for literature review, significantly saving time and effort in information gathering and organization.

In fact, the pharmaceutical industry has long faced a structural challenge: the approval of pediatric indications for new drugs often lags significantly behind those for adults. This delay can sometimes extend to nearly 10 years, reflecting both the scientific complexities and regulatory caution involved in drug development for special populations.

At JPM 2026, 24 Chinese innovative biopharmaceutical companies presented in the main conference and Asia-Pacific sessions, while an even greater number completed significant licensing deals with multinational corporations during the event. In key focus areas at JPM 2026, such as antibody-drug conjugates (ADCs), metabolic diseases, and cell and gene therapies, Chinese innovative drugs have become an indispensable source of value.

Although policies and market forces have driven the expansion of the third-party medical service industry, as the sector evolves to a new stage, bottlenecks such as high customer acquisition costs, limited service scenarios, weak post-examination management, and difficulties in extending high-quality resources to grassroots markets have become increasingly prominent, constraining further market growth. The unique advantages of internet medical service offer a viable pathway to overcome these challenges.

It is reported that gastric cancer is a highly prevalent malignant tumor globally, with its incidence and mortality rates both ranking fifth among all cancer types. The number of gastric cancer patients in China is exceptionally large.

On December 31, 2025, Zelgen Biopharmaceuticals announced that it has entered into a strategic collaboration and option agreement with an affiliate of AbbVie. for the global development and commercialization of ZG006 (Alveltamig). The candidate, ZG006, is a novel trispecific T-cell engager targeting DLL3, currently in late-stage clinical development for the treatment of small cell lung cancer and other DLL3-expressing malignant tumors.

Recently, disease control and prevention centers across China have rolled out subsidized vaccination initiatives for herpes zoster. Two approved herpes zoster vaccines in China have undergone significant price reductions: the second dose of GSK's imported recombinant herpes zoster vaccine (brand name: Shingrix®) is now offered free of charge, while the domestic herpes zoster live attenuated vaccine produced by BCHT (brand name: Gan Wei) is available at a discount of 30% to 80%.

On the opening day of the A-share market in 2026 (January 5), Chinese brain-computer interface concept stocks collectively opened higher. Among them, Beoka surged over 29.98%, while SanBo, Xiangyu Medical, Mehow Medical, Apon Medical, Chieftain, and Vishee Medical all hit the 20% daily price limit. Innovative Medical and Thalys Medical rose over 10%, with Biotest and Vishee Medical, among others, also gaining. As of the market close that day, the stock prices continued to exhibit a high-opening-and-high-trading trend, reflecting strong market expectations for the commercial prospects of brain-computer interface technology.

This trend not only marks the transition of bispecific antibody technology from a niche field to a mainstream focus but also signals its potential to replace traditional monoclonal antibodies and antibody-drug conjugates as the cornerstone of next-generation biopharmaceutical development.

Compared with the first-generation products of international industry leaders, Sonico-CX offers four major advantages: a smaller balloon folded outer diameter (0.041 inches, approximately 1.04 mm), a higher number of available pulses (120 pulses), more uniform energy delivery (enabling 360-degree circumferential and intermittent shockwave emission), and a more comprehensive range of catheter specifications (7 sizes ranging from 2.5 mm to 4.0 mm).

NouvNeu001 is now the first iPSC product globally to hold both RMAT and Fast Track Designation (FTD) status, the latter having been granted on August 15, 2025. This rapid sequential recognition highlights the FDA's strong confidence in its clinical data.

Leveraging its leading expertise in small-molecule technology, Jacobio has become one of the companies with the most advanced clinical progress in this field. This collaboration extends beyond a traditional asset licensing agreement to include co-development within the Chinese market, marking the entry into a new phase of partnership models between Chinese innovative drug companies and global pharmaceutical giants.

TSHR is a G protein-coupled receptor (GPCR) located on the surface of thyroid cells and orbital-related tissues. It plays a key regulatory role in the synthesis and secretion of thyroid hormones, as well as in thyroid cell proliferation.

MTS-105 is a first-in-class mRNA-encoded T cell engager (TCE) therapy candidate for hepatocellular carcinoma (HCC), delivered via METiS's proprietary liver-targeted LNP system. Study results demonstrate that, once delivered to and taken up within the liver, the mRNA is translated in situ and secreted locally as high level of bispecific antibodies, which rapidly penetrate HCC tissues.

JS212 is a recombinant humanized bispecific antibody-drug conjugate (ADC) targeting both the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), intended primarily for the treatment of advanced malignant solid tumors.

As a leading biopharmaceutical company in China, Innovent Biologics has built a robust product pipeline of more than 30 new drug candidates, spanning major therapeutic areas, including oncology, autoimmune diseases, cardiovascular and metabolic diseases, and ophthalmology.

Evidently, within the medical device sector influenced by various market and policy factors, ophthalmic surgical microscopes have emerged as one of the most resilient and strongly growing sub-segments in China. While the increase in winning bid volume for these devices is partly driven by rising surgical demand, from a product perspective, why are ophthalmic surgical microscopes selling so well?